When does the mavacamten patent expire?
The patent expiry date for mavacamten depends on which specific patent (and which jurisdiction) you mean, because each patent has its own term and may be extended or adjusted for regulatory factors. The provided information here does not include any patent numbers, jurisdictions, or listed expiry dates, so I can’t state an accurate single expiry date for “mavacamten” from this context.
Which patents control mavacamten’s market exclusivity?
For small-molecule drugs like mavacamten, market exclusivity timelines are usually driven by multiple layers, such as:
- the earliest “first filing” that sets the base patent term,
- later patent families (e.g., formulations, specific uses, dosing regimens),
- any patent term adjustments/extensions,
- and separate exclusivity protections in addition to patents (jurisdiction-dependent).
To give the correct expiry date, you would need the specific patent family (or at least country/region).
What you can share so I can give the exact expiry date
If you share any of the following, I can map it to an expiry date more precisely:
- the country/region (e.g., US, EP/UK, Canada, Japan, etc.)
- one patent number or application number
- a patent-family identifier (assignee + publication number)
- a link to the patent record you’re looking at
How to check mavacamten patent expiry yourself (quick ways)
Common ways to find the controlling expiry date include searching:
- USPTO Patent Center (US patents)
- Espacenet (EP/WO families)
- Google Patents (family + “expires” indicators)
These will show the listed expiration/term for each patent document, which you then reconcile to identify which one blocks generic entry in that jurisdiction.
Next step
Tell me the jurisdiction (e.g., “US” or “EU/UK”) and, if you have it, the patent number or link you’re looking at. Then I can give the exact mavacamten patent expiry date for that specific protection.